Molecular diagnosis of prostate cancer

The diagnosis, staging, and management of prostate cancer as we know it today is greatly dependent on our ability to measure serum prostate-specific antigen (PSA) concentration. Nevertheless, because serum PSA concentration, particularly when less than 10 ng/mL, reflects the presence of benign prost...

Full description

Saved in:
Bibliographic Details
Published in:Current urology reports 2004-06, Vol.5 (3), p.203-211
Main Authors: Canto, Eduardo I, Shariat, Shahrokh F, Slawin, Kevin M
Format: Article
Language:English
Subjects:
Biomarkers, Tumor - blood
Humans
Male
Mass Spectrometry - methods
Prostate-Specific Antigen - blood
Prostate-Specific Antigen - chemistry
Prostatic Neoplasms - blood
Prostatic Neoplasms - diagnosis
Tissue Kallikreins - blood
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The diagnosis, staging, and management of prostate cancer as we know it today is greatly dependent on our ability to measure serum prostate-specific antigen (PSA) concentration. Nevertheless, because serum PSA concentration, particularly when less than 10 ng/mL, reflects the presence of benign prostatic hyperplasia more often than cancer, there is a clear need for more specific prostate cancer markers. The most promising new markers for prostate cancer are the various molecular forms of free PSA. Mass spectrometry also is emerging as a potential tool in prostate cancer screening. Because it is unlikely that any one marker will have 100% sensitivity and specificity, as new serum markers are tested, nomograms that incorporate multiple independently predictive parameters for the detection of prostate cancer will become indispensable in our efforts to improve prostate cancer screening.
ISSN:1527-2737
1534-6285
DOI:10.1007/s11934-004-0038-2